Suprofen

Summary

Suprofen (CHEMBL956) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE07) targeting PTGS1 and PTGS2; indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE07
• Targets: 2 (PTGS1, PTGS2)
• Indications: 1 condition
• Chemistry: 260.31 Da · C14H12O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL956
Name	Suprofen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5359
ChEBI	CHEBI:9362
ATC	M01AE07
Molecular formula	C14H12O3S
Molecular weight	260.31
InChIKey	MDKGKXOCJGEUJW-UHFFFAOYSA-N

SMILES: CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O

IUPAC name: 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid

ChEBI definition: An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, antirheumatic drug, peripheral nervous system drug, drug allergen.

Also known as: NSC-303611, Profenal, R-25,061, R-25061, Racemic suprofen, Srendam, Sulproltin, Suprofen, Suprofene, Suprofeno, Sutoprofen, TN-762

Patent coverage: 7,961 distinct patent families (32,428 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGS1	COX-1	Inhibition	6.25	0%	P23219
PTGS2	COX-2	Inhibition	5.56	0%	P35354

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Lysine-specific demethylase 4E, Inositol monophosphatase 1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Relaxin receptor 1, Beta-lactamase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.55	AC50	284	nM	CHEMBL_ACT_25174524
PTGS1	6.25	IC50	560	nM	CHEMBL_ACT_2242275
PTGS2	5.56	IC50	2750	nM	CHEMBL_ACT_2242285
CYP2C9	5.43	Ki	3700	nM	CHEMBL_ACT_6075058
P97697	5.3	Potency	5012	nM	CHEMBL_ACT_4407290
P00811	5.2	Potency	6310	nM	CHEMBL_ACT_4684038

Target pathways

Aggregated over 2 target gene(s): PTGS1, PTGS2.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	2	PTGS1, PTGS2
COX reactions	1	PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives	1	PTGS2
Interleukin-10 signaling	1	PTGS2
Interleukin-4 and Interleukin-13 signaling	1	PTGS2
Biosynthesis of DHA-derived SPMs	1	PTGS2
Biosynthesis of EPA-derived SPMs	1	PTGS2
Biosynthesis of DPAn-3 SPMs	1	PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives	1	PTGS2

Dominant GO biological processes

GO term	Targets
prostaglandin biosynthetic process	2
response to oxidative stress	2
regulation of blood pressure	2
cyclooxygenase pathway	2
regulation of cell population proliferation	2
long-chain fatty acid biosynthetic process	2
lipid metabolic process	2
fatty acid metabolic process	2
fatty acid biosynthetic process	2
prostaglandin metabolic process	2
prostanoid biosynthetic process	2
cellular oxidant detoxification	2
embryo implantation	1
response to nematode	1
response to selenium ion	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

407 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ACEMETACIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ASPIRIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
BROMFENAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CAPSAICIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CAPTOPRIL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CARPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CELECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CIANIDANOL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DEXIBUPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DEXKETOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DICLOFENAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
DOXORUBICIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ESFLURBIPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ETODOLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ETORICOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
FLURBIPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
GLAFENINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
IBUPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
INDOMETHACIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
KETOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
KETOROLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LEVODOPA	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LOXOPROFEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
LUMIRACOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MECLOFENAMIC ACID	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MEFENAMIC ACID	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MELOXICAM	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MOFEZOLAC	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
MONOBENZONE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
NAPROXEN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
NIMESULIDE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
OMADACYCLINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
OXAPROZIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
PIROXICAM	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
PRIMAQUINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
RANITIDINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
ROFECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
SELINEXOR	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TEGASEROD	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TELOTRISTAT	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TOLMETIN	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
TROGLITAZONE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
VALDECOXIB	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
VORTIOXETINE	ChEMBL	Phase 4 (approved)	PTGS1, PTGS2
CURCUMIN	ChEMBL	Phase 3	PTGS1, PTGS2
RESVERATROL	ChEMBL	Phase 3	PTGS1, PTGS2
CIMICOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
DERACOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
ENOFELAST	ChEMBL	Phase 2	PTGS1, PTGS2
FIROCOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
FLUFENAMIC ACID	ChEMBL	Phase 2	PTGS1, PTGS2
LICOFELONE	ChEMBL	Phase 2	PTGS1, PTGS2
MAVACOXIB	ChEMBL	Phase 2	PTGS1, PTGS2
MIROPROFEN	ChEMBL	Phase 2	PTGS1, PTGS2
NIFLUMIC ACID	ChEMBL	Phase 2	PTGS1, PTGS2
PHENOTHIAZINE	ChEMBL	Phase 2	PTGS1, PTGS2
PIRMAGREL	ChEMBL	Phase 2	PTGS1, PTGS2